Anti-Human EGFR Reference Antibody (Depatuxizumab, RUO)
- Catalog number: BS10304
- Availability: In Stock
$176.00
- Ex Tax: $176.00
Description: Depatuxizumab (BS10304) is a research-grade recombinant antibody targeting HER1. Produced in mammalian cells with native-like glycosylation.
Highlights:
• Research Grade — For PK/PD studies, assay development, and ADA research.
• Native Glycosylation — Mammalian expression ensures native-like patterns.
Host species: Humanized
Isotype: IgG1-kappa
Species reactivity: Human
Immunogen:
Form: Liquid
Storage instructions:
Storage buffer: 0.01M PBS, pH7.4.
Concentration: 1mg/ml
Purity: >95% as determined by SDS-PAGE.
Clonality: Monoclonal
Applications: Research Grade Biosimilar
Target: HER1,Receptortyrosine-proteinkinaseerbB-1,Proto-oncogenec-ErbB-1,Epidermalgrowthfactorreceptor,EGFR,ERBB1,ERBB
Purification: Protein A/G purified from cell culture supernatant.
Endotoxin level: <1EU/mg, determined by LAL gel clotting assay
Expression system: Mammalian Cells
Stability and Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Alternative Names: ABT-806,ABT-414,unconjugate:ABT-806,CAS:1471999-69-5
Background: Epidermal growth factor receptor (EGFR/ERBB1) is a ~134 kDa protein. Receptor tyrosine kinase binding ligands of the EGF family and activating several signaling cascades to convert extracellular cues into appropriate cellular responses. Known ligands include EGF, TGFA/TGF-alpha, AREG, epigen/EPGN, BTC/betacellulin, epiregulin/EREG and HBEGF/heparin-binding EGF. Ligand binding triggers receptor homo- and/or heterodimerization and autophosphorylation on key cytoplasmic residues. The phosphorylated receptor recruits adapter proteins like GRB2 which in turn activates complex downstream signaling cascades. Activates at least 4 major downstream signaling cascades including the RAS-RAF-MEK-ERK, PI3 kinase-AKT, PLCgamma-PKC and STATs modules. EGFR is the therapeutic target of cetuximab (Erbitux) and panitumumab (Vectibix).
References:
1. Arcaro, A. et al. (2000) Molecular and cellular biology 20, 3817-30. PMID: 10805725
2. Runkle, KB. et al. (2016) Molecular cell 62, 385-396. PMID: 27153536
3. Chen, WS. et al. (1989) Cell 59, 33-43. PMID: 279096
4. Bu, J. et al. (2022) Acta biochimica et biophysica Sinica 54, 400-408. PMID: 35538033
5. Garrett, TP. et al. (2002) Cell 110, 763-73. PMID: 12297049
6. Kochupurakkal, BS. et al. (2005) The Journal of biological chemistry 280, 8503-12. PMID: 15611079
7. Kim, J. et al. (2007) Cancer research 67, 9229-37. PMID: 17909029
8. Lu, C. et al. (2010) Molecular and cellular biology 30, 5432-43. PMID: 20837704
Note: For research use only. Not suitable for clinical or therapeutic use.
Highlights:
• Research Grade — For PK/PD studies, assay development, and ADA research.
• Native Glycosylation — Mammalian expression ensures native-like patterns.
Host species: Humanized
Isotype: IgG1-kappa
Species reactivity: Human
Immunogen:
Form: Liquid
Storage instructions:
Storage buffer: 0.01M PBS, pH7.4.
Concentration: 1mg/ml
Purity: >95% as determined by SDS-PAGE.
Clonality: Monoclonal
Applications: Research Grade Biosimilar
Target: HER1,Receptortyrosine-proteinkinaseerbB-1,Proto-oncogenec-ErbB-1,Epidermalgrowthfactorreceptor,EGFR,ERBB1,ERBB
Purification: Protein A/G purified from cell culture supernatant.
Endotoxin level: <1EU/mg, determined by LAL gel clotting assay
Expression system: Mammalian Cells
Stability and Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Alternative Names: ABT-806,ABT-414,unconjugate:ABT-806,CAS:1471999-69-5
Background: Epidermal growth factor receptor (EGFR/ERBB1) is a ~134 kDa protein. Receptor tyrosine kinase binding ligands of the EGF family and activating several signaling cascades to convert extracellular cues into appropriate cellular responses. Known ligands include EGF, TGFA/TGF-alpha, AREG, epigen/EPGN, BTC/betacellulin, epiregulin/EREG and HBEGF/heparin-binding EGF. Ligand binding triggers receptor homo- and/or heterodimerization and autophosphorylation on key cytoplasmic residues. The phosphorylated receptor recruits adapter proteins like GRB2 which in turn activates complex downstream signaling cascades. Activates at least 4 major downstream signaling cascades including the RAS-RAF-MEK-ERK, PI3 kinase-AKT, PLCgamma-PKC and STATs modules. EGFR is the therapeutic target of cetuximab (Erbitux) and panitumumab (Vectibix).
References:
1. Arcaro, A. et al. (2000) Molecular and cellular biology 20, 3817-30. PMID: 10805725
2. Runkle, KB. et al. (2016) Molecular cell 62, 385-396. PMID: 27153536
3. Chen, WS. et al. (1989) Cell 59, 33-43. PMID: 279096
4. Bu, J. et al. (2022) Acta biochimica et biophysica Sinica 54, 400-408. PMID: 35538033
5. Garrett, TP. et al. (2002) Cell 110, 763-73. PMID: 12297049
6. Kochupurakkal, BS. et al. (2005) The Journal of biological chemistry 280, 8503-12. PMID: 15611079
7. Kim, J. et al. (2007) Cancer research 67, 9229-37. PMID: 17909029
8. Lu, C. et al. (2010) Molecular and cellular biology 30, 5432-43. PMID: 20837704
Note: For research use only. Not suitable for clinical or therapeutic use.
Images
-
SEC-HPLCSEC-HPLC detection for Research Grade Depatuxizumab.
-
SDS-PAGESDS-PAGE for Research Grade Depatuxizumab.
